



A.P. Pharma to Hold Second Quarter Conference Call August 4, 2003

July 24, 2003

REDWOOD CITY, Calif.--(BUSINESS WIRE)--July 24, 2003--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will release its 2003 second quarter financial results prior to market open on Monday, August 4, 2003.

Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Monday, August 4, 2003 to discuss the results and to answer questions.

To participate in the live call by telephone, please dial 888-803-8275 from the U.S., and for international callers, please dial 706-634-1287. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation number 1702289.

Individuals interested in listening to the conference call via the Internet may do so by visiting www.appharma.com. A replay will be available on the Company's Web site.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer. Initial targeted areas of application for the Company's drug delivery technology include pain management, inflammation, oncology and ophthalmology applications. The Company's product development programs are funded by royalties from topical products currently marketed by pharmaceutical partners and by proceeds from the divestiture of its cosmeceutical product lines as well as fees it receives from collaborative partners. For further information visit the Company's Web site at www.appharma.com.

CONTACT: A.P. Pharma, Inc., Redwood City
Gordon Sangster, 650-366-2626
or
Lippert/Heilshorn & Associates
Investor relations:
Bruce Voss (bvoss@lhai.com)
Jody Cain (jcain@lhai.com)
310-691-7100

SOURCE: A.P. Pharma, Inc.